Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Susceptibility to Inflammatory Coronary Heart DiseaseReport as inadecuate




Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Susceptibility to Inflammatory Coronary Heart Disease - Download this document for free, or read online. Document in PDF available to download.

BioMed Research International - Volume 2015 2015, Article ID 315174, 6 pages -

Research Article

Department of Cardiology, The Second Affiliated Hospital, Wenzhou Medical University, Wenzhou 325000, China

Department of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14214, USA

Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Huatuo Road, No. 1, Fuzhou 350112, China

Received 24 July 2014; Accepted 1 September 2014

Academic Editor: Kai Huang

Copyright © 2015 Kangting Ji et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Macrophage migration inhibitory factor MIF is a proinflammatory cytokine. This study explored the association of 173G-C polymorphism of the MIF gene with coronary heart disease CHD. Methods. Sequencing was carried out after polymerase chain reaction with DNA specimens from 186 volunteers without CHD and 70 patients with CHD. Plasma MIF levels on admission were measured by ELISA. Patients were classified into either stable angina pectoris SAP or unstable angina pectoris UAP. Genotype distribution between cases and controls and the association of patients’ genotypes with MIF level and plaque stability were statistically evaluated ethical approval number: 2012-01. Results. The frequency of the C genotype was higher in CHD patients than in the control . The frequency of the 173

CC genotype was higher in CHD patients than in the control . The plasma MIF level was higher in MIF173

C carriers than in MIF173

G carriers . CHD patients had higher plasma MIF levels than the control . Patients with UAP had higher plasma MIF levels than patients with SAP . Conclusions. These data suggest that MIF −173G-C polymorphism may be related to the development of CHD in a Chinese population. Plasma MIF level is a predictor of plaque stability. This trial is registered with NCT01750502 .





Author: Kangting Ji, Xiaoyan Wang, Ji Li, Qin Lu, Guoqiang Wang, Yangjing Xue, Suqin Zhang, Lu Qian, Wenwu Wu, Yongjin Zhu, Lupi

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents